Reverse transcription and amplification of RNA with simultaneous degradation of DNA

Information

  • Patent Grant
  • 8309303
  • Patent Number
    8,309,303
  • Date Filed
    Monday, March 27, 2006
    18 years ago
  • Date Issued
    Tuesday, November 13, 2012
    12 years ago
Abstract
The invention relates to a method for processing RNA, in particular, a RNA reaction method and kits for carrying out said RNA reaction method.
Description
CROSS REFERENCE TO RELATED APPLICATIONS

The present application is a National Phase Application of International Application No. PCT/EP2006/002771, filed Mar. 27, 2006, which claims priority to European Patent Application No. 05007157.0 filed Apr. 1, 2005, which applications are incorporated herein fully by this reference.


The present invention relates to a method for the treatment of RNA, in particular an RNA reaction method, as well as kits for performing an RNA reaction method according to the invention.


Many techniques in molecular biology lead to the analysis of ribonucleic acids (RNA). In order to be able to analyse RNA it must be purified of all inhibitory and contaminating substances. Thus, for example, contamination with genomic deoxyribonucleic acid (DNA) can have an inhibitory effect or lead to false positive results. A number of techniques of molecular RNA analysis begin with the reverse transcription of RNA into cDNA. cDNA is very similar to or even identical to genomic DNA in both structure and sequence. Therefore contamination by genomic DNA can lead to false results if cDNA is to be analysed (e.g. photometric determination of cDNA quantities or its quantification by PCR).


In order to be able to analyse RNA with certainty it is therefore necessary either to separate all other distorting nucleic acids, for example genomic DNA, from the RNA before a corresponding analysis, or to degrade them into their individual components. A separation method used for some time for DNA and RNA is the so-called density gradient centrifugation. Standard substances for density gradient centrifugation are caesium chloride (CsCl) and saccharose. In the case of CsCl a density gradient is established in the equilibrium state during centrifugation dependent upon, for example, the density of the starting solution, in which each macromolecule is aligned in the zone corresponding to its intrinsic density in the gradient. In order to visualise the nucleic acid bands established after centrifugation in the centrifugation vessel ethidium bromide is added to the CsCl solution, which is incorporated into the nucleic acid and which fluoresces in UV light. This method enables the reliable separation of individual DNA fragments which are otherwise very difficult to distinguish from one another owing to the close sedimentation rates of these fragments. In CsCl density gradient centrifugation gradients with density values between 1.0 and 1.9 g/ml are normally used. Since the buoyant density of RNA is normally greater than 1.9 g/ml, in an equilibrium centrifugation (also called isopycnic centrifugation) RNA settles to the bottom of the sample vessel in a gradient whose upper density limit lies at 1.9 g/ml, whereas all other types of molecule (including DNA) form respective bands within the gradient. Thus, corresponding separation operation leads to a good separation of RNA and DNA. However, the density gradient centrifugation method is relatively expensive owing to the chemicals used, very elaborate in apparatus and also very time consuming (in most rotors long centrifugation runs of up to 2 days are necessary until an equilibrium has been established in a conventional CsCl gradient).


Therefore a made has been made to the isolation of RNA whereby either during or after RNA preparation a DNase or several DNases is/are added to the experimental batch in order to degrade DNA contamination enzymatically. Systems (so-called “kits”) for this purpose have been marketed by the company QIAGEN, Hilden, Germany under the name “RNeasy Micro Kit” and “RNeasy Fibrous Tissue Kit” and by the company Promega, Madison/WI, USA, under the name “SV Total RNA Isolation System”. However, these RNA preparation methods do not lead to the isolation of pure RNA. The RNA isolated is present rather more as a material that is contaminated to different extents with genomic DNA, salts, inhibitors, etc. The level of purity achievable with the above-named kits may indeed be adequate for many applications, but this is not the case for a number of other areas of application (e.g. RT-PCR).


A further method for RNA purification is also used in which chromatographical methods are employed (e.g. ion exchange chromatography, oligo-dT chromatography) in order to enrich RNA further and to reduce the amount of DNA. However, it is not possible to purify ribosomal RNA with this method.


Finally, US patent application no. 20020042052 describes further a method for the removal of nucleic acid impurities from a batch for amplification reactions. Here a thermolabile DNase is used which always degrades unwanted double-stranded DNA in the amplification batch prior to the actual amplification reaction. Owing to its thermolability, the DNase used is irreversibly deactivated at the latest during the first temperature increase to above 90° C. during the PCR reaction. The PCR reaction can only then be commenced when the DNase reaction is concluded. A simultaneity of the DNA degradation reaction and an RNA reaction is thus not suggested by the method known from the cited American published specification.


Also, all these more recent methods are, however, in part time consuming, cost intensive and can possibly lead to cross-contamination during the simultaneous processing of several RNA preparations. Furthermore it is also the case with the previously known methods described above that DNA degradation does not take place concurrently with the RNA reaction or RNA analysis, but the DNA degradation is always carried out prior to the actual RNA reaction or RNA analysis.


Thus, the problem underlying the present invention is to provide a method for RNA analysis that does not have the disadvantages of the known methods described above. The new method has to be cost effective and less time consuming and keep the expenditure on apparatus within limits.


The invention solves this problem by the method according to independent Claim 1 and a kit according to the independent Claim 13. Further advantageous embodiments, aspects and details of the invention are provided by the dependent claims, the description, the examples and the figures.


The present invention thus relates to an RNA reaction method, characterised in that an RNA reaction and a degradation of double-stranded DNA present takes place in the same vessel, whereby the degradation of the double-stranded DNA is carried out by an enzyme with DNA double-strand-specific endonuclease activity. The RNA reaction and the degradation of double-stranded DNA present preferably takes place at the same time. This has the considerable advantage that it is no longer necessary to wait with the start of a RNA reaction until the unwanted double-stranded DNA present in the reaction batch has been fully degraded or at least so far degraded that it no longer interferes with the RNA reaction or the associated analysis reaction. Also, by means of the method according to the invention the risk that impurities are introduced into the reaction batch by frequent opening of the reaction vessel is reduced


Also, in the method according to the invention the RNA reaction on the one hand and the DNA degradation on the other can be carried out at the same temperature. The temperature can thereby lie, for example, in the range from 10 to 80° C., preferably 20 to 70° C., in particular 20 to 60° C.


Thus for the first time the invention combines DNA decontamination of the sample with the RNA reaction in a simultaneous process, that is, the DNA decontamination on the one hand and the RNA reaction or the RNA analysis on the other run sequentially or concurrently or in parallel in one and the same reaction vessel. Typical RNA reactions are, for example, reverse transcription, 1 step RT-PCR (reverse transcription polymerase chain reaction in one step) or tagging reactions of RNA, but are not limited to these.


The present invention thus ensures a degradation of undesirable double-stranded DNA (e.g. genomic DNA (gDNA), linear or circular DNA, e.g. plasmid DNA) at the same time as reactions that contain RNA as analyte (e.g. reverse transcription, see above). The degradation of the double-stranded DNA takes place within the reaction that contains RNA as analyte by means of an enzyme with DNA double-strand-specific endonuclease activity. This enzyme is a deoxyribonuclease (DNase) or several DNases that specifically cleaves or cleave completely or at least partially by endonucleolytic hydrolysis DNA present as an intra- or intermolecular double strand. Furthermore, these DNases are characterised in that a cleavage of DNA single strands and RNA single strands and also RNA and DNA that occur as RNA-DNA hybrids does not take place, or only to a very small extent. With this invention it is possible for the first time for a double-strand-specific DNase to be used simultaneously for the degradation of double-stranded DNA in the presence of, for example, a cDNA synthesis reaction in which an RNA is transcribed into single-stranded DNA, whereby the single-stranded cDNA just formed in the synthesis process is degraded only very slightly or not at all. The DNA double-strand-specific endonucleases that may be used according to the invention can be thermostable or thermolabile.


As previously mentioned above, the present invention relates to the combination of reduction in dsDNA contamination on the one hand and RNA reactions on the other in a simultaneous process. Important thereby are the reaction conditions that equally allow DNA degradation to take place as well as also the reaction with the RNA, whereby the dsDNA decontamination is carried out, for example, with a double-strand-specific DNase.


A “DNA contamination” in an RNA isolate is defined as any double-stranded deoxyribonucleic acid molecule which can be of different origin and occurs together with the RNA in the same reaction vessel as undesired molecule. Double-strandedness of DNA can also occur when a single-stranded DNA is present folded back through self-hybridisation and thus is present double-stranded at least for a time.


The double-stranded DNA (dsDNA) can originate from the original biological material from which the RNA has been also isolated. This can be nuclear, plastidal or mitochondrial in nature. The dsDNA can be also transferred to the original biological material from an external source by biological means, be it by infection, transformation, fusion, incorporation or similar and can thus be, for example, of viral, prokaryotic or eukaryotic origin. In addition, the DNA can also be transferred to the original biological material by unnatural means such as, for example, electroporation, transformation, transfection or other techniques. It can be genomic DNA, plasmid DNA, doubles-stranded oligonucleotides (such as, for example, primer-dimers) or other forms of double-stranded DNA. Moreover, the double-stranded DNA can also be introduced into the RNA preparation either during or after RNA isolation.


Defined as “RNA reaction” are, for example:

  • (1) any form of change to the RNA such as, for example, degradation, tagging, extension, modification or similar. The RNA can be present thereby as single-stranded, double-stranded or as hybrid molecule (e.g. RNA-DNA hybrid);
    • where degradation is concerned it is preferably a specific degradation in which RNA is degraded selectively by, for example, ribozyme, RNase H and/or siRNA. An RNase H-enzyme obtained, for example, by mutation or chemical modification can also be used as RNase H;
  • (2) any form of conversion in which RNA is used as template for polymerase reactions such as, for example, (a) reverse transcription or (b) transcription by RNA polymerases or similar;
    • in respect of (a): the reverse transcription can be carried out by mutated or non-mutated RNA-dependent DNA polymerases such as, for example, reverse transcriptases from viruses, retrotransposons, bacteria, etc. These can have RNase H activity, or reverse transcriptases can be used that are so mutated that the RNase H activity of the reverse transcriptase was restricted or is not present (e.g. MMLV-RT RNase H). RNA-dependent DNA synthesis (reverse transcription) can also be carried by enzymes that show altered nucleic acid dependency through mutation or modified reaction conditions and thus obtain the function of the RNA-dependent DNA polymerase. Cited here as example is Tth-DNA polymerase, which is DNA-dependent, and by using modified reaction conditions RNA can also be used as matrix.
    • In respect of (b): an RNA polymerase reaction starting from RNA as matrix can be carried out with mutated and non-mutated RNA-dependent RNA polymerases from, for example, viruses, prokaryotes or eukaryotes. RNA-dependent RNA syntheses can also be carried out with enzymes that have a changed nucleic acid dependency through mutation or modified reaction conditions and thus obtain the function of the RNA-dependent RNA polymerase. Cited here as example is an RNA amplification method that uses a T7-RNA polymerase and RNA as matrix (EP 1 056 884);
  • (3) any form of conversion in which the RNA functions as catalyst such as, for example, ribozymes, etc.;
  • (4) any form of binding reaction. Different binding partners can be involved in the binding reaction whereby at least one partner is RNA. The following binding reactions are feasible such as, for example, RNA-RNA, RNA-DNA, RNA-PNA (known most widely as hybridisation), RNA antibody reactions, RNA aptamer reactions, recognition reactions of RNA with other molecules such as, for example, antibiotics or similar;
  • (5) any form of composite reactions in which the above-mentioned reactions (1) to (4) are a component of the overall reaction such as, for example, linear RNA amplification reactions (e.g. Eberwine, epiclones, Nugen), exponential RNA amplification methods (e.g. NASBA, TMA) or other amplification methods (e.g. SAGE, RT-PCR, RCA).


When in respect of the present invention discussion relates to RNA as “reaction participant” or of an “RNA reaction method”, an “RNA reaction” or an “RNA analysis”, this then means that the RNA is indeed involved in a respective reaction or analysis but must not necessarily be changed. Also, in accordance with the present invention the RNA is called a “reaction participant” in reactions from which RNA is recovered unchanged (e.g. when the RNA is used as catalyst or matrix), or when discussion refers to an “RNA reaction method”, an RNA reaction” or an “RNA analysis”.


If in connection with the present invention use is made of “at the same time” or simultaneity”, “in parallel”, “simultaneous” or similar it is to be understood that a dsDNA degradation and the RNA reaction takes place in the same reaction vessel. Degradation of the dsDNA contamination and the RNA reaction are thus carried out at the same time and in the one and the same reaction batch. Simultaneity is meant to express that the RNA reaction and a degradation of the dsDNA contamination takes place at the same time in the same reaction vessel and under the same reaction conditions.


It is also advantageous in the method according to the invention, in particular opposite the method known from US 20020042052, that the method according to the invention can take place at a uniform temperature, that is that the RNA reaction and a dsDNA degradation can take place at the same temperature. In addition, it is also beneficial opposite the method known from US 20020042052 that in the method according to the invention it is not necessary to open the reaction vessel again after the dsDNA degradation with DNase and to add a new enzyme (that would possible be irreversibly damaged by warming to over 90° C.) as in that way unnecessary contamination can be avoided.


According to the present invention the RNA reaction is limited by the reaction conditions which not only determine the RNA reaction, but simultaneously should also allow the degradation of the dsDNA contamination. This does not mean that optimal conditions are set respectively for the reaction of the RNA and for degradation of the dsDNA, but the conditions for the RNA reaction and a degradation of the DNA can throughout be adapted to one another. The present invention makes it possible for the first time for an RNA reaction and degradation of dsDNA to take place at the same time in the one and the same reaction vessel.


A “deoxyribonuclease”, or abbreviated “DNase”, is defined here as an enzyme that specifically completely or at least partially cleaves (degrades) by endonucleolytic hydrolysis DNA present as a intra- or intermolecular double strand, that is an enzyme with DNA double-strand-specific DNA endonuclease activity. This DNase is thus characterised in that a degradation or cleavage of RNA single strands and of DNA single strands and also of a RNA or DNA that is present as RNA-DNA hybrid does not take place or only to a negligibly small extent. The DNases within the meaning of the present invention are either sequence-specific or cleave the dsDNA non-specifically. Both variants can be used within the context of the present invention. It is likewise possible to use thermolabile and/or thermostable DNases. Thus it is clear to the appropriate person skilled in the art in the light of the respective RNA reaction or also of the respective follow-up reaction which enzyme is suitable.


By a “degradation” of the dsDNA it is to be understood that the degradation process progresses so far in every case that the DNA shows only a slight or no a disruptive effect on the RNA reaction(s) or the subsequent applications. A degradation can, but need not necessarily, mean a complete disintegration of double-stranded DNA into its individual components (nucleotides). Within the meaning of the invention the degradation of the dsDNA occurs at least partially at the same time as the RNA reaction.





The diagrams show:



FIG. 1 a photo of an agarose gel which shows the result of an electrophoresis according to Example 1;



FIG. 2 a bar chart from which the results of an experiment on the possible effect of the reverse transcriptase reaction by various nucleases are seen (Example 2);



FIG. 3 a photo of an agarose gel which shows the result of an electrophoresis according to Example 3;



FIG. 4 a diagram which shows the results listed in Table 1 in graphical form; and



FIG. 5 a bar chart which shows the effect of pancreatic DNase I on a cDNA and gDNA signal according to Example 7.





The following enzymes can be used for the degradation of double-stranded DNA, in particular in reverse transcriptase reactions:

    • 1) sequence-independent (sequence-non-specific) endonucleases: these endonucleases can be a native enzyme (isolate from an organism) or prepared from genetically modified organisms (GMOs) or mutants of these enzymes. An example of a sequence-independent endonuclease is DNase I, which according to the invention is particularly preferred for the degradation of dsDNA;
    • 2) sequence-specific endonucleases: these endonucleases can be a native enzyme (isolate from an organism) or prepared from genetically modified organisms (GMOs) or mutants of these enzymes. Examples of sequence-specific endonucleases are the enzymes Alu I or Hae III. Mixtures of sequence-specific endonucleases can also be used.
    • 3) Combinations of sequence-specific endonucleases and sequence non-specific endonuclease.


The endonucleases are generally used in such a manner that the reaction batch contains about 0.01 to about 100 U of enzyme activity, preferably about 0.05 to about 20 U, more preferably about 0.1 to about 10 U. According to international agreement, enzyme activity expressed as 1 U (unit, enzyme unit) corresponds to a) for sequence-non-specific DNA double-strand-specific endonucleases the amount of enzyme that is necessary to convert 1 μmol substrate per minute at 25° C. under optimal conditions, and b) for sequence-specific DNA double-strand-specific restriction endonucleases the amount of enzyme that is necessary to convert 1 μg Lambda-DNA per hour at 37° C. under optimal conditions.


In the case of an RT-PCR the degradation of the dsDNA is carried out in the presence of a reverse transcriptase. Suitable reverse transcriptases are, for example, reverse transcriptases from retroviruses such as, for example, HIV, AMV, MMLV, Omniscript® (QIAGEN GmbH), Sensiscript® (QIAGEN GmbH) etc., or also from retrotransposons. The reverse transcriptases can correspond to the original organism in their amino acid sequence, or they can also have deviations therefrom, for example, changes that lead to loss of RNase H activity, change the processivity or influence the thermostability of the enzyme. DNA polymerases which originally have little or no reverse transcriptase activity can also be used and can be used as reverse transcriptase through the use of suitable reaction conditions or through mutations (e.g. rTth polymerase).


The aqueous buffer solution in which the degradation dsDNA takes place in the presence of reverse transcriptase comprises at least:

    • 1) a DNA double-strand-specific endonuclease (as described above);
    • 2) a reverse transcriptase (as described above);
    • 3) a buffer substance which buffers the pH value of the experimental batch;
    • 4) a pH value between 6 and 10, particularly preferred between 7 and 9; and
    • 5) divalent cations which support a reverse transcriptase reaction and the enzymatic degradation of genomic DNA such as, for example, Mg2+ (in a concentration range between 0.1 and 50 mM), Mn2+ (in a concentration range between 0.01 and 10 mM), or Ca2+ (in a concentration range between 0.01 and 50 mM).


The reaction batch can also contain other components such as, for example, other enzymes, divalent cations or salts. A heat-stable DNA polymerase can thus also be present.


The reaction temperature can lie, for example, between 10 and 70° C., preferably between 15° C. and 60° C., most particularly preferred between 20° C. and 50° C.


The present invention relates further to a kit for performing a method according to any of claims 1 to 12, whereby the kit comprises at least one reverse transcriptase, a DNA double-strand-specific endonuclease and a reaction buffer for performing a method according to any of the claims 1 to 12 and a dsDNA degradation in one vessel. Preferably the kits are such for performing a cDNA synthesis or for undertaking a 1-step RT-PCR. If the kit serves the performing of a 1-step PCR it can additionally contain a heat-stable DNA polymerase.


The invention is described more closely in the following by means of the examples.


EXAMPLE 1

In each case 1 μg gDNA and 1 μg total-RNA from HeLa cells were mixed for use in a reverse transcriptase reaction. The reverse transcriptase reaction was carried out in an aqueous medium that contained an oligo-dT primer, dNTPs, an RNase inhibitor, a buffer (Buffer RT from the Omniscript RT Kit of QIAGEN GmbH, Hilden, Germany) for the reverse transcription and a reverse transcriptase (Omniscript®, trademark of QIAGEN GmbH, Hilden, Germany). In addition different double-strand-specific DNases were added:

  • (1) Alu I restriction endonuclease in an amount of 10 U (obtainable from Roche, Mannheim, Germany);
  • (2) Hae III restriction endonuclease in an amount of 10 U (Roche).
  • (3) RNase-free DNase I in an amount of 10 U (Roche);
  • (4) Alu I restriction endonuclease in an amount of 10 U (Roche) and Hae III restriction endonuclease in an amount of 10 U (Roche).


No DNase was added to an additional reaction batch. This batch served as control. The reaction mixture was incubated for one hour at 37° C. and then (A) analysed by PCR for cDNA degradation and (B) tested for RNA integrity and DNA degradation on an agarose gel (1.2%).


The result is shown in FIG. 1. The degradation of gDNA is recognisable with the use of the DNases Alul, Hae III, DNase I or with the mixture of the DNases Alu I and Hae III, whereby the integrity of the rRNA was not impaired. Likewise, it could be seen on the basis of the RT-PCR signals of the β-actin transcript that the presence of the DNases Alu I, Hae III, DNase I or the mixture of the DNases Alu I and Hae III lead to no change in signal intensity, which demonstrates that the DNases used did not impair the RT reaction.


EXAMPLE 2

Each time 1 ng total RNA from HeLa cells was mixed with 1 μg of a 0.2-9.5 kB RNA-ladder (Invitrogen) for use in a reverse transcriptase reaction. The reverse transcriptase reaction was carried out in an aqueous medium that contained an oligo-dT primer, dNTPs, RNase inhibitor, a buffer (Buffer RT from the Omniscript RT Kit of QIAGEN GmbH, Hilden, Germany) for the reverse transcription and a reverse transcriptase (Omniscript®, trade mark of QIAGEN GmbH, Hilden, Germany). In addition the DNA double-strand-specific-endonuclease DNase I (RNase-free DNase I) was added. Exonuclease VII (“Exo VII”) was added to further batches.


The DNase I (from bovine pancreas; obtainable from Roche, Mannheim, Germany) and the exonuclease VII were used in different amounts. No nuclease was added to a further reaction batch. This batch served as positive control. The batch with exonuclease VII served as negative control. Exonuclease VII is not double-strand-specific and able to degrade single-stranded DNA. The respective reaction mixtures were incubated for one hour at 37° C. and then analysed by PCR for cDNA degradation. The whole β-actin transcript was amplified in the PCR.


The result is shown in FIG. 2. The DNase I led to no impairment of the reverse transcriptase reaction. This is clear opposite the positive control. DNase I shows a signal intensity for RT-PCR fragments which corresponds to the intensity of the positive control. Only the single-strand-specific nuclease exonuclease VII used as negative control led to a considerable degradation of the single-strand-cDNA, so that no RT-PCR specific signal could be found.


EXAMPLE 3

Each of 1 μg genomic DNA and 1 μg total-RNA from HeLa cells were mixed for use in a reverse transcriptase reaction. The reverse transcriptase reaction was carried out in an aqueous medium that contained an oligo-dT primer, dNTPs, an RNase inhibitor and a buffer (Buffer RT from the Omniscript RT Kit of QIAGEN GmbH, Hilden, Germany) for the reverse transcription. In addition different amounts of double-strand-specific nucleases were added:

  • (1) Alu I restriction endonuclease in an amount of 0-10 U (Roche, Mannheim, Germany);
  • (2) Hae III restriction endonuclease in an amount of 0-10 U (Roche, Mannheim, Germany); and
  • (3) RNase-free DNase I in an amount of 0-10 U (Roche, Mannheim, Germany).


Reverse transcriptase was added to one set of the batches in order to be able to investigate the influence of nucleases on the synthesis of single-stranded cDNA. No reverse transcriptase was added to a second set of batches in order to be able to follow the degradation of genomic DNA. The reaction mixtures were incubated for one hour at 37° C. and then analysed by PCR. In the batches in which cDNA synthesis was followed the complete cDNA of the β-actin transcript was amplified. In the batches in which the degradation of genomic DNA was followed a region from the 5′-end of the β-actin gene was amplified. Since the primer set spans an intron the genomic amplificate shows a size of >600 bp, whereas the amplificate of the cDNA has a size of ca. 200 bp.


The result is shown in FIG. 3. FIG. 3 shows a photo or a 1% agarose gel on whose tracks batches with different nuclease concentrations were investigated. It can be seen from FIG. 3 that the reverse transcription was not impaired by the presence of the nucleases tested, which can be recognised in that the cDNA bands for all of the three nucleases tested remain clearly visible at all concentrations, see the upper region of FIG. 3. In contrast it is equally clear that the use of nucleases leads to a more or less complete degradation of the genomic DNA used when a certain minimal amount of nuclease (5 U) is added, see lower region of FIG. 3.


EXAMPLE 4

Each time 150 ng total RNA from HeLa cells were mixed with 150 ng gDNA in order to carry out a DNase reaction under reverse transcriptase reaction conditions. The reaction was carried out in an aqueous medium that contained oligo-dT primer, dNTPs, an RNase inhibitor and a buffer (Buffer RT from the Omniscript RT Kit of QIAGEN GmbH, Hilden, Germany) for the reverse transcription. In addition 0; 0.1; 0.5; or 2.5 units double-strand-specific nuclease (RNase-free DNase I) were added to the batches. Also 0 mM, 0.5 mM, 1 mM, 1.5 mM, 2 mM or 2.5 mM magnesium chloride were added to the batches. No reverse transcriptase was added in order to investigate the DNase I activity under reverse transcriptase reaction conditions. The reaction mixtures were incubated for one hour at 37° C. The DNA degradation was then analysed by quantitative real-time PCR. For this 1 μl of the reaction mixture each time was used for the real-time PCR. A primer pair that amplified a 200 bp fragment from the 5′-end of the β-actin was used. The resulting amplificate was detected with SYBR green.


The result is shown in FIG. 4 and Table 1. The degradation of the genomic DNA was determined from the CT value and is dependent upon the amount of RNase-free DNase I used. The activity of RNase-free DNase I can be modulated by the addition of extra magnesium chloride when the highest CT values were obtained for 2.5 U DNase and 2 mM MgCl2.













TABLE 1







DNase I
DNase I
DNase I



DNase I
(0.1 U)
(0.5 U)
(2.5 U)


MgCl2
(0 U)
CT cycle
CT cycle
CT cycle




















0
mM
22.7
22.5
23.5
32.9


0.5
mM
22.8
22.9
26.1
36.2


1
mM
22.9
22.8
28.1
41.5


1.5
mM
22.9
23.3
32.3
41.1


2
mM
22.6
23.3
31.4
46.2


2.5
mM
22.9
24.3
29.4
43.2









EXAMPLE 5

Each time 150 ng total RNA from HeLa cells were mixed with 0 ng or 150 ng gDNA for use in a reverse transcriptase reaction. The reaction was carried out in an aqueous medium that contained an oligo-dT primer, dNTPs, RNase inhibitor and a buffer (Buffer RT from the Omniscript RT Kit of QIAGEN GmbH, Hilden, Germany) for the revere transcription. In addition, 2.5 units of double-strand-specific endonuclease (RNase-free DNase I) are added to a part of the batches. One set of the batches received a reverse transcriptase in order to be able to investigate the influence of the nucleases on the synthesis of single-stranded cDNA. No reverse transcriptase was added to a second batch in order to be able follow the degradation of the genomic DNA. The reaction mixtures were incubated for one hour at 37° C. The cDNA synthesis and the DNA degradation were then analysed by quantitative real time PCR. In each case 1 μl and 0.1 μl of the reverse transcriptase reaction were used for the real time PCR. A primer pair that amplified a 210 bp fragment from the 3′-end of the β-actin was used. The resulting amplificate was detected with SYBR green.


The result of this investigation was that the reverse transcription was not impaired by the presence of RNase-free DNase I. By use of RNase-free DNase I the genomic DNA was degraded more than 1000 times. At the same time the cDNA generated was not, or only insignificantly, digested. The result is collated in Table 2.


The DNase step can also be carried out in a very brief reaction before the actual RNA-modifying reaction, whereby, however, as in the above batches the DNase remains in the reaction mixture and is not removed from the system by heat inactivation or a purification step.













TABLE 2






CT cycle

CT cycle




150 ng Hela
Mean
0 ng Hela
Mean


Transferred volumes
DNA
value
DNA
value







Without reverse
22.1
22.2
32.6
33.4


transcription,
22.4

33.5


without DNase 1 μl
22.0

34.0


Without reverse
32.9
32.2
34.0
33.5


transcription,
31.8

35.2


with DNase 1 μl
31.8

31.3


Without reverse
25.3
25.4
34.4
33.2


transcription,
25.4

32.4


without DNase 0.1 μl
25.6

32.9


Without reverse
34.3
34.0
32.6
32.4


transcription,
33.8

31.5


with DNase 0.1 μl
33.9

33.1


With reverse
13.3
13.4
13.4
13.4


transcription,
13.5

13.3


with DNase 1 μl
13.4

13.5


With reverse
13.6
13.8
13.8
13.7


transcription,
13.9

13.5


without DNase 1 μl
13.8

13.7


With reverse
16.3
16.5
15.9
16.3


transcription,
16.5

16.4


with DNase 0.1 μl
16.6

16.7


With reverse
16.0
16.3
16.2
16.5


transcription,
16.5

16.6


without DNase 0.1 μl
16.3

16.6









EXAMPLE 6

Each time 10 μg to 1 μg total RNA from HeLa cells were mixed with identical amounts of gDNA for use in a reverse transcriptase reaction. The reaction was carried out in an aqueous medium that contained an oligo-dT primer, random octamers, dNTPs, RNase inhibitor and a buffer (gDNA Wipeout Buffer and Quantiscript RT Buffer from the QuantiTecto Reverse Transcription Kit of QIAGEN GmbH, Hilden, Germany) for the reverse transcription. Also 2.5 units double-strand-specific endonuclease (RNase-free DNase I) were added to a part of the batches. Reverse transcriptase was added to one set of the batches in order to be able to investigate the influence of the nucleases on the synthesis of single-stranded cDNA. No reverse transcriptase was added to a second set of batches in order to be able to follow the degradation of genomic DNA. Before the actual cDNA synthesis the DNase step was carried out for 2 minutes at 37° C. Only then were the reaction mixtures incubated for 15 minutes in the presence of the reverse transcriptase at 37° C. Next, the cDNA synthesis and the DNA degradation analysed by quantitative real time PCR. In each case 1 μl of the reverse transcriptase reaction was used for the real time PCR. A QuantiTect Gene Expression Assay (QIAGEN GmbH, Hilden, Germany) was used for the Gen RPSLA, together with the QuantiTect Probe PCR Kit (also from QIAGEN), which contains all necessary reaction components such as HotStar Taq DNA Polymerase (QIAGEN), reaction buffer and dNTPs. The HotStar Taq DNA Polymerase was reactivated for 15 minutes at 95° C., after which the PCR was carried out for 50 cycles with the following temperature profile: 15 sec 56° C., 30 sec 76° C., 30 sec 94° C. The reverse transcriptase reaction was deactivated for 5 min at 95° C. before use in the PCR reaction. The extent of the genomic DNA depletion is reported in the following table 3 in CT values:









TABLE 3







Difference−


DNase/+DNase














1 μg
100 ng
10 ng
1 ng
100 pg
10 pg

















RNA 1/DNA 1
20.6
18.7
18.1
17.8
14.2
5.4


RNA 2/DNA 2
23.3
20.7
20.0
13.6
8.3
10.4


RNA 2/DNA 1
23.1
21.7
21.4
18.8
14.8
12.1









The result shows that by use of RNase-free DNase I, whose incubation is carried out prior to the actual reverse transcriptase step, the genomic DNA is generally depleted more than 1000 times.


A further batch was used to demonstrate that the DNase step can also be integrated into the process of a so-called 1-step RT-PCR. In a 1-step RT-PCR reaction the whole reaction batch including all reagents necessary for the reverse transcriptase step and the subsequent PCR step are combined. The reaction is started with the reverse transcription and continues directly into the PCR step without opening the reaction vessel. The following example shows that a DNase step can also be introduced into such a continuous method scheme that does not allow further operator interaction.


EXAMPLE 7

In each case 20 ng total RNA from HeLa cells and 20 ng high molecular gDNA were used in each 1-step RT-PCR. 150 μM CaCl2 were added to the reaction. Each reaction was carried out with the QuantiTect RT-PCR Kit (QIAGEN GmbH, Hilden, Germany), which contains all necessary reaction components such as reverse transcriptase, HotStar Taq DNA polymerase, reaction buffer and dNTPs. The reactions were initiated with and without DNase I. The reverse transcriptase was not used in reactions that were solely to detect genomic DNA in order not to obtain an additional signal from the cDNA. Reaction batches in which DNase I was used received 0.25 units DNase I. A transcript region for which identical sequences occur in genomic DNA was detected as target gene. The PCR products that were generated from genomic DNA and cDNA had the same size and consequently should be amplified and detected with the same efficiency.


The result is shown in FIG. 5 and can be summarised as follows. The CT value of genomic DNA increases through the use DNase by more than 6 cycles, which corresponds to a 100 fold gDNA degradation, whereas the CT value of cDNA changes only insignificantly. This leads to the conclusion that a gDNA removal step is also usable in I-step RT-PCR and leads to a significant degradation of genomic DNA, whereas cDNA remains intact, or is only insignificantly degraded. The increase in the CT value on using RNA (cDNA) is essentially attributable to the depletion of the genomic DNA contained in the RNA sample.

Claims
  • 1. A method of analyzing RNA, comprising, degradation of double-stranded DNA and an RNA reaction, wherein the degradation of double-stranded DNA and the RNA reaction are carried out in the same reaction vessel at the same time and at the same temperature, wherein the degradation of double-stranded DNA is carried out with an enzyme with DNA double-strand-specific endonuclease activity, wherein the RNA reaction is a conversion reaction, wherein the RNA is used as a template for a polymerase reaction, and wherein the RNA is analyzed after the RNA reaction.
  • 2. The method of claim 1, wherein the RNA reaction comprises a tagging, extension or modification of the RNA.
  • 3. The method of claim 1, wherein the conversion reaction is a reverse transcription reaction.
  • 4. A method of analyzing RNA, comprising, degradation of double-stranded DNA and an RNA reaction, wherein the degradation of double-stranded DNA and the RNA reaction are carried out in the same reaction vessel at the same time and at the same temperature, wherein the degradation of double-stranded DNA is carried out with an enzyme with DNA double-strand-specific endonuclease activity, wherein the RNA acts as a catalyst in the RNA reaction, thereby analyzing RNA.
  • 5. The method of claim 1, wherein the RNA is involved in a binding reaction in the RNA reaction.
  • 6. The method of claim 1, wherein the RNA reaction is a combined reaction, wherein at least two of the reactions selected from the group consisting of a tagging of the RNA, an extension of the RNA, a modification of the RNA, or a conversion reaction are involved.
  • 7. The method of claim 1, wherein the degradation of DNA is carried out with an enzyme selected from the group consisting of DNase 1 and restriction endonucleases.
  • 8. The method of claim 1, wherein the method is carried out at a pH value of between 6 and 10.
  • 9. The method of claim 1, wherein the reaction comprises divalent cations.
  • 10. The method of claim 9, wherein the divalent cations are selected from the group consisting of Mg2+, Mn2+ and Ca2+.
  • 11. A method of analyzing RNA, comprising, degradation of double-stranded DNA and an RNA reaction, wherein the degradation of double-stranded DNA and the RNA reaction are carried out in the same reaction vessel at the same time and at the same temperature, wherein the degradation of double-stranded DNA is carried out with an enzyme with DNA double-strand-specific endonuclease activity, wherein the RNA reaction is a specific degradation reaction, wherein the RNA is selectively degraded, and wherein the RNA is selectively degraded by a ribozyme, RNase H or by siRNA-induced RNA degradation, thereby analyzing RNA.
  • 12. The method of claim 8, wherein the method is carried out at a pH value of between 7 and 9.
  • 13. The method of claim 1, wherein the double stranded DNA is degraded by RNAse-free DNase I.
  • 14. The method of claim 1, wherein the double-stranded DNA is degraded by a restriction endonuclease.
  • 15. The method of claim 1, wherein the degradation of double stranded DNA is carried out in the presence of an RNAse inhibitor.
Priority Claims (1)
Number Date Country Kind
05007157 Apr 2005 EP regional
PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/EP2006/002771 3/27/2006 WO 00 10/6/2009
Publishing Document Publishing Date Country Kind
WO2006/103039 10/5/2006 WO A
US Referenced Citations (372)
Number Name Date Kind
2264423 Wingenroth Dec 1941 A
3395018 Read Jul 1968 A
3654090 Wilhelmus et al. Apr 1972 A
3687808 Merigan, Jr. et al. Aug 1972 A
3921105 Brgelz Nov 1975 A
3983421 Yogore Sep 1976 A
3995018 Sjoquist Nov 1976 A
4299916 Litman et al. Nov 1981 A
4469863 Ts'o et al. Sep 1984 A
4476301 Imbach et al. Oct 1984 A
4748111 Dattagupta et al. May 1988 A
4816567 Cabilly et al. Mar 1989 A
4837003 Nicolotti Jun 1989 A
4845205 Huynh Dinh et al. Jul 1989 A
4883750 Whiteley et al. Nov 1989 A
4937183 Ultee et al. Jun 1990 A
4940670 Rhodes Jul 1990 A
4965188 Mullis et al. Oct 1990 A
4981957 Lebleu et al. Jan 1991 A
4994373 Stavrianopoulos et al. Feb 1991 A
4994557 Kassis et al. Feb 1991 A
5001050 Blanco et al. Mar 1991 A
5023243 Tullis Jun 1991 A
5034506 Summerton et al. Jul 1991 A
5043272 Hartley Aug 1991 A
5106727 Hartley et al. Apr 1992 A
5118800 Smith et al. Jun 1992 A
5130238 Malek et al. Jul 1992 A
5130302 Spielvogel et al. Jul 1992 A
5134066 Rogers et al. Jul 1992 A
5137806 LeMaistre et al. Aug 1992 A
5166315 Summerton et al. Nov 1992 A
5175273 Bischofberger et al. Dec 1992 A
5177196 Meyer, Jr. et al. Jan 1993 A
5185444 Summerton et al. Feb 1993 A
5187060 Cerutti et al. Feb 1993 A
5188897 Suhadolnik et al. Feb 1993 A
5198543 Blanco et al. Mar 1993 A
5214134 Weis et al. May 1993 A
5216141 Benner Jun 1993 A
5235033 Summerton et al. Aug 1993 A
5242794 Whiteley et al. Sep 1993 A
5262311 Pardee et al. Nov 1993 A
5264423 Cohen et al. Nov 1993 A
5264562 Matteucci Nov 1993 A
5264564 Matteucci Nov 1993 A
5264567 Numata et al. Nov 1993 A
5268486 Waggoner et al. Dec 1993 A
5273638 Konrad et al. Dec 1993 A
5276019 Cohen et al. Jan 1994 A
5278302 Caruthers et al. Jan 1994 A
5286717 Cohen et al. Feb 1994 A
5319080 Leumann Jun 1994 A
5321131 Agrawal et al. Jun 1994 A
5328824 Ward et al. Jul 1994 A
5334711 Sproat et al. Aug 1994 A
5354668 Auerbach Oct 1994 A
5359044 Cook et al. Oct 1994 A
5367066 Urdea et al. Nov 1994 A
5367069 Beck et al. Nov 1994 A
5393878 Leumann Feb 1995 A
5399676 Froehler Mar 1995 A
5405938 Summerton et al. Apr 1995 A
5405939 Suhadolnik et al. Apr 1995 A
5409818 Davey et al. Apr 1995 A
5412087 McGall et al. May 1995 A
5427930 Birkenmeyer et al. Jun 1995 A
5429807 Matson et al. Jul 1995 A
5432272 Benner Jul 1995 A
5434257 Matteucci et al. Jul 1995 A
5443986 Haughland et al. Aug 1995 A
5445934 Fodor et al. Aug 1995 A
5446137 Maag et al. Aug 1995 A
5451067 Pieper Sep 1995 A
5451203 Lamb Sep 1995 A
5453496 Caruthers et al. Sep 1995 A
5455166 Walker Oct 1995 A
5455233 Spielvogel et al. Oct 1995 A
5457187 Gmeiner et al. Oct 1995 A
5459255 Cook et al. Oct 1995 A
5466677 Baxter et al. Nov 1995 A
5466786 Buhr et al. Nov 1995 A
5470967 Huie et al. Nov 1995 A
5476427 Fujima Dec 1995 A
5476786 Huston Dec 1995 A
5476925 Letsinger et al. Dec 1995 A
5484908 Froehler et al. Jan 1996 A
5489677 Sanghvi et al. Feb 1996 A
5500341 Spears Mar 1996 A
5502177 Matteucci et al. Mar 1996 A
5510270 Fodor et al. Apr 1996 A
5514785 Van Ness et al. May 1996 A
5516134 Crawford et al. May 1996 A
5516663 Backman et al. May 1996 A
5516664 Hyman May 1996 A
5519126 Hecht May 1996 A
5519134 Acevedo et al. May 1996 A
5521065 Whiteley et al. May 1996 A
5523204 Singer et al. Jun 1996 A
5525711 Hawkins et al. Jun 1996 A
5536821 Agrawal et al. Jul 1996 A
5538871 Nuovo et al. Jul 1996 A
5539082 Nielsen et al. Jul 1996 A
5541306 Agrawal et al. Jul 1996 A
5541307 Cook et al. Jul 1996 A
5547843 Studier et al. Aug 1996 A
5550111 Suhadolnik et al. Aug 1996 A
5552540 Haralambidis Sep 1996 A
5556748 Douglas Sep 1996 A
5556771 Shen et al. Sep 1996 A
5556772 Sorge et al. Sep 1996 A
5561045 Dorval et al. Oct 1996 A
5561225 Maddry et al. Oct 1996 A
5563037 Sutherland et al. Oct 1996 A
5563253 Agrawal et al. Oct 1996 A
5563912 Yasunaga et al. Oct 1996 A
5565339 Bloch et al. Oct 1996 A
5567811 Misiura et al. Oct 1996 A
5571799 Tkachuk et al. Nov 1996 A
5576427 Cook et al. Nov 1996 A
5587361 Cook et al. Dec 1996 A
5587469 Cook et al. Dec 1996 A
5591609 Auerbach Jan 1997 A
5591722 Montgomery et al. Jan 1997 A
5593836 Niemiec et al. Jan 1997 A
5594121 Froehler et al. Jan 1997 A
5596086 Matteucci et al. Jan 1997 A
5596091 Switzer Jan 1997 A
5597909 Urdea et al. Jan 1997 A
5599695 Pease et al. Feb 1997 A
5599921 Sorge et al. Feb 1997 A
5602240 De Mesmaeker et al. Feb 1997 A
5608046 Cook et al. Mar 1997 A
5610289 Cook et al. Mar 1997 A
5610300 Altmann et al. Mar 1997 A
5614389 Auerbach Mar 1997 A
5614390 McCaslin et al. Mar 1997 A
5614617 Cook et al. Mar 1997 A
5618704 Sanghvi et al. Apr 1997 A
5623070 Cook et al. Apr 1997 A
5625050 Beaton et al. Apr 1997 A
5627053 Usman et al. May 1997 A
5629158 Uhlen May 1997 A
5629179 Mierendorf et al. May 1997 A
5633360 Bischofberger et al. May 1997 A
5635602 Cantor et al. Jun 1997 A
5639599 Ryder et al. Jun 1997 A
5639873 Barascut et al. Jun 1997 A
5646265 McGee Jul 1997 A
5648213 Reddy et al. Jul 1997 A
5648245 Fire et al. Jul 1997 A
5654413 Brenner Aug 1997 A
5658873 Bertsch-Frank et al. Aug 1997 A
5663312 Chaturvedula Sep 1997 A
5665539 Sano et al. Sep 1997 A
5670633 Cook et al. Sep 1997 A
5677437 Teng et al. Oct 1997 A
5677439 Weis et al. Oct 1997 A
5679509 Wheeler et al. Oct 1997 A
5681941 Cook et al. Oct 1997 A
5683985 Chu et al. Nov 1997 A
5691136 Lupski et al. Nov 1997 A
5695933 Schalling et al. Dec 1997 A
5700920 Altmann et al. Dec 1997 A
5710028 Eyal et al. Jan 1998 A
5712100 Nakahama et al. Jan 1998 A
5714320 Kool Feb 1998 A
5714331 Buchardt et al. Feb 1998 A
5719262 Buchardt et al. Feb 1998 A
5728526 George, Jr. et al. Mar 1998 A
5733733 Auerbach Mar 1998 A
5736365 Walker et al. Apr 1998 A
5744305 Fodor et al. Apr 1998 A
5766891 Shuman Jun 1998 A
5770408 Sato Jun 1998 A
5795714 Cantor et al. Aug 1998 A
5800992 Fodor et al. Sep 1998 A
5800994 Martinelli et al. Sep 1998 A
5807674 Tyagi Sep 1998 A
5817529 Wu Oct 1998 A
5821084 Olmsted et al. Oct 1998 A
5824517 Cleuziat et al. Oct 1998 A
5830711 Barany et al. Nov 1998 A
5849544 Harris et al. Dec 1998 A
5854033 Lizardi Dec 1998 A
5856096 Windle et al. Jan 1999 A
5866329 Demetriou et al. Feb 1999 A
5866336 Nazarenko et al. Feb 1999 A
5871697 Rothberg et al. Feb 1999 A
5871914 Nathan Feb 1999 A
5871921 Landegren et al. Feb 1999 A
5871928 Fodor et al. Feb 1999 A
5874260 Cleuziat et al. Feb 1999 A
5876924 Zhang et al. Mar 1999 A
5876932 Fischer Mar 1999 A
5876992 De Rosier et al. Mar 1999 A
5880473 Ginestet Mar 1999 A
5882912 Sandstrom et al. Mar 1999 A
5882935 Hirai et al. Mar 1999 A
5886329 Kim Mar 1999 A
5888731 Yager et al. Mar 1999 A
5891636 Van Gelder et al. Apr 1999 A
5909132 Trofimenkoff et al. Jun 1999 A
5912124 Kumar Jun 1999 A
5912148 Eggerding Jun 1999 A
5914229 Loewy Jun 1999 A
5925517 Tyagi et al. Jul 1999 A
5942391 Zhang et al. Aug 1999 A
5942609 Hunkapiller et al. Aug 1999 A
5945312 Goodman et al. Aug 1999 A
5955933 Nishihara et al. Sep 1999 A
5959095 Martinelli et al. Sep 1999 A
5962223 Whiteley et al. Oct 1999 A
5968743 Matsunaga et al. Oct 1999 A
5976806 Mahajan et al. Nov 1999 A
5985639 Christianson et al. Nov 1999 A
5998175 Akhavan-Tafti Dec 1999 A
6007994 Ward et al. Dec 1999 A
6008373 Waggoner et al. Dec 1999 A
6013431 Soderlund et al. Jan 2000 A
6013444 Dau et al. Jan 2000 A
6017703 Kinders et al. Jan 2000 A
6020138 Akhavan-Tafti Feb 2000 A
6025139 Yager et al. Feb 2000 A
6027889 Barany et al. Feb 2000 A
6027923 Wallace Feb 2000 A
6033881 Himmler et al. Mar 2000 A
6037130 Tyagi et al. Mar 2000 A
6054274 Sampson et al. Apr 2000 A
6057105 Hoon et al. May 2000 A
6064274 Nayebi et al. May 2000 A
6077668 Kool Jun 2000 A
6077674 Schleifer et al. Jun 2000 A
6087133 Dattagupta et al. Jul 2000 A
6087476 Kenten et al. Jul 2000 A
6096880 Kool Aug 2000 A
6117635 Nazarenko et al. Sep 2000 A
6124120 Lizardi Sep 2000 A
6132728 Beachy et al. Oct 2000 A
6140055 Todd et al. Oct 2000 A
6143495 Lizardi et al. Nov 2000 A
6169816 Ravkin Jan 2001 B1
6183960 Lizardi Feb 2001 B1
6197533 Dawkes et al. Mar 2001 B1
6203984 Hu et al. Mar 2001 B1
6210884 Lizardi Apr 2001 B1
6214587 Dattagupta et al. Apr 2001 B1
6221603 Mahtani Apr 2001 B1
6225636 Ginestet May 2001 B1
6235502 Weissman et al. May 2001 B1
6242188 Dattagupta et al. Jun 2001 B1
6248535 Danenberg et al. Jun 2001 B1
6255082 Lizardi Jul 2001 B1
6255636 Cochran, II et al. Jul 2001 B1
6259807 Ravkin Jul 2001 B1
6274320 Rothberg et al. Aug 2001 B1
6277607 Tyagi et al. Aug 2001 B1
6280949 Lizardi Aug 2001 B1
6287765 Cubicciotti Sep 2001 B1
6287768 Chenchik et al. Sep 2001 B1
6287776 Hefti Sep 2001 B1
6287824 Lizardi Sep 2001 B1
6288220 Kambara et al. Sep 2001 B1
6291183 Pirrung et al. Sep 2001 B1
6291187 Kingsmore et al. Sep 2001 B1
6291193 Khodadoust Sep 2001 B1
6291669 Kwiatkowski et al. Sep 2001 B1
6294664 Ravikumar et al. Sep 2001 B1
6297006 Drmanac et al. Oct 2001 B1
6300073 Zhao et al. Oct 2001 B1
6312902 Shultz et al. Nov 2001 B1
6316229 Lizardi et al. Nov 2001 B1
6323009 Lasken et al. Nov 2001 B1
6329150 Lizardi et al. Dec 2001 B1
6344329 Lizardi Feb 2002 B1
6355431 Chee et al. Mar 2002 B1
6361940 Van Ness et al. Mar 2002 B1
6365729 Tyagi et al. Apr 2002 B1
6368801 Faruqi Apr 2002 B1
6403319 Lizardi et al. Jun 2002 B1
6417340 Mirkin et al. Jul 2002 B1
6440707 Kwok et al. Aug 2002 B1
6458544 Miller Oct 2002 B1
6458556 Hayashizaki Oct 2002 B1
6472185 McCasky Feazel et al. Oct 2002 B2
6475736 Stanton, Jr. Nov 2002 B1
6479235 Schumm et al. Nov 2002 B1
6479242 Guo et al. Nov 2002 B1
6479244 Belouchi et al. Nov 2002 B1
6498023 Abarzua Dec 2002 B1
6506563 Ward et al. Jan 2003 B1
6531283 Kingsmore et al. Mar 2003 B1
6573051 Alsmadi et al. Jun 2003 B2
6617137 Dean et al. Sep 2003 B2
6632609 Lizardi Oct 2003 B2
6635425 Bandaru et al. Oct 2003 B2
6642034 Lizardi Nov 2003 B2
6670126 Kingsmore et al. Dec 2003 B2
6686157 Ward et al. Feb 2004 B2
6703228 Landers et al. Mar 2004 B1
6703885 Fan et al. Mar 2004 B1
6706519 Kellogg et al. Mar 2004 B1
6713257 Shoemaker et al. Mar 2004 B2
6777183 Abarzua Aug 2004 B2
6797474 Lizardi Sep 2004 B2
6811986 Bandaru et al. Nov 2004 B2
6830884 Hafner et al. Dec 2004 B1
6861222 Ward et al. Mar 2005 B2
6861231 Shao Mar 2005 B2
6884586 Van Ness et al. Apr 2005 B2
6921642 Kingsmore et al. Jul 2005 B2
6942972 Farooqui et al. Sep 2005 B2
6977148 Dean et al. Dec 2005 B2
6977153 Kumar et al. Dec 2005 B2
RE39007 Dattagupta et al. Mar 2006 E
7041480 Abarzua May 2006 B2
7074600 Dean et al. Jul 2006 B2
7297485 Bornarth et al. Nov 2007 B2
7358047 Hafner et al. Apr 2008 B2
7553619 Kumar et al. Jun 2009 B2
7618776 Lizardi Nov 2009 B2
20010041340 Kingsmore et al. Nov 2001 A1
20020009716 Abarzua Jan 2002 A1
20020026046 Pasloske et al. Feb 2002 A1
20020042052 Nilsen et al. Apr 2002 A1
20020119465 Zhao et al. Aug 2002 A1
20020120409 Cao et al. Aug 2002 A1
20020172972 Tabor et al. Nov 2002 A1
20020192649 Lizardi Dec 2002 A1
20020192658 Ward et al. Dec 2002 A1
20020197694 Shao Dec 2002 A1
20030008313 Wiltshire Jan 2003 A1
20030022167 Alsmadi et al. Jan 2003 A1
20030032014 Wei et al. Feb 2003 A1
20030032024 Lizardi Feb 2003 A1
20030059786 Ward et al. Mar 2003 A1
20030092901 Farooqui et al. May 2003 A1
20030099954 Miltenyi et al. May 2003 A1
20030108902 Abarzua Jun 2003 A1
20030121338 Yates Jul 2003 A1
20030129658 Yamaji et al. Jul 2003 A1
20030143613 Kingsmore et al. Jul 2003 A1
20030152932 Kumar et al. Aug 2003 A1
20030165948 Alsmadi et al. Sep 2003 A1
20030175788 Alsmadi et al. Sep 2003 A1
20030186288 Spivack et al. Oct 2003 A1
20030207267 Lasken et al. Nov 2003 A1
20030207323 Bandaru et al. Nov 2003 A1
20030219751 Lao et al. Nov 2003 A1
20030235849 Lizardi et al. Dec 2003 A1
20040018489 Ma et al. Jan 2004 A1
20040063144 Lizardi Apr 2004 A1
20040091857 Nallur et al. May 2004 A1
20040121338 Alsmadi et al. Jun 2004 A1
20040126770 Kumar et al. Jul 2004 A1
20040191784 Abarzua et al. Sep 2004 A1
20040248103 Feaver et al. Dec 2004 A1
20040248105 Kumar Dec 2004 A1
20040265897 Lizardi Dec 2004 A1
20050003369 Christians et al. Jan 2005 A1
20050003410 Frazer et al. Jan 2005 A1
20050069938 Wang Mar 2005 A1
20050069939 Wang Mar 2005 A1
20050074804 Wang Apr 2005 A1
20050079523 Hafner et al. Apr 2005 A1
20050112639 Wang May 2005 A1
20060083683 Hsei et al. Apr 2006 A1
20060126764 Eklund et al. Jun 2006 A1
20060166227 Kingsmore et al. Jul 2006 A1
20060188892 Latham et al. Aug 2006 A1
20080096258 Korfhage et al. Apr 2008 A1
20110112173 Brown et al. May 2011 A1
Foreign Referenced Citations (92)
Number Date Country
8417391 Feb 1992 AU
649066 May 1994 AU
5850996 Nov 1996 AU
714486 Jan 2000 AU
749560 Jun 2002 AU
0 070 685 Jul 1982 EP
0 128 332 Dec 1984 EP
0 310 030 Apr 1989 EP
0 320 308 Jun 1989 EP
0 356 021 Feb 1990 EP
0 379 369 Jul 1990 EP
0 395 398 Oct 1990 EP
0 439 182 Jul 1991 EP
0 466 520 Jan 1992 EP
0 505 012 Sep 1992 EP
0 531 080 Mar 1993 EP
0 278 340 Aug 1993 EP
0278340 Aug 1993 EP
0 640 691 Mar 1995 EP
0 667 393 Aug 1995 EP
0 678 582 Oct 1995 EP
0 745 690 Dec 1996 EP
0 756 009 Jan 1997 EP
1 056 884 Dec 2001 EP
1056884 Dec 2001 EP
1 132 470 Sep 2005 EP
1132470 Sep 2005 EP
2332516 Jun 1999 GB
4262799 Sep 1992 JP
4304900 Oct 1992 JP
5130869 May 1993 JP
5146299 Jun 1993 JP
2005304396 Nov 2005 JP
WO 9416106 Jul 1984 WO
WO 9416108 Jul 1984 WO
WO 8909824 Oct 1989 WO
WO 9011372 Oct 1990 WO
WO 9106643 May 1991 WO
WO 9108307 Jun 1991 WO
WO 9116446 Oct 1991 WO
WO 9201813 Feb 1992 WO
WO 9424312 Oct 1994 WO
WO 9503430 Feb 1995 WO
WO 9503432 Feb 1995 WO
WO 9525180 Sep 1995 WO
WO 9522623 Nov 1995 WO
WO 9535390 Dec 1995 WO
WO 9600795 Jan 1996 WO
WO 9614406 May 1996 WO
WO 9633207 Oct 1996 WO
WO 9802449 Jan 1997 WO
WO 9707235 Feb 1997 WO
WO 9814610 Apr 1997 WO
WO 9717076 May 1997 WO
WO 9717471 May 1997 WO
WO 9719193 May 1997 WO
WO 9720948 Jun 1997 WO
WO 9742346 Nov 1997 WO
WO 9804746 Feb 1998 WO
WO 9816248 Apr 1998 WO
WO 9839485 Sep 1998 WO
WO 9918241 Apr 1999 WO
WO 9931276 Jun 1999 WO
WO 9954452 Oct 1999 WO
WO 0004193 Jan 2000 WO
WO 0015779 Mar 2000 WO
WO 0015849 Mar 2000 WO
WO 0036141 Jun 2000 WO
WO 0070095 Nov 2000 WO
WO 0071562 Nov 2000 WO
WO 0120039 Mar 2001 WO
WO 0127326 Apr 2001 WO
WO 0138580 May 2001 WO
WO 0140516 Jun 2001 WO
WO 0161037 Aug 2001 WO
WO 0164952 Sep 2001 WO
WO 0177390 Oct 2001 WO
WO 0179420 Oct 2001 WO
WO 0188190 Nov 2001 WO
WO 0197616 Dec 2001 WO
WO 0200934 Jan 2002 WO
WO 0202792 Jan 2002 WO
WO 02053780 Jul 2002 WO
WO 02077256 Oct 2002 WO
WO 02103058 Dec 2002 WO
WO 03008538 Jan 2003 WO
WO 03033724 Apr 2003 WO
WO 03066908 Aug 2003 WO
WO 03072809 Sep 2003 WO
WO 2004009814 Jan 2004 WO
WO 2004058987 Jul 2004 WO
WO 2004061119 Jul 2004 WO
Related Publications (1)
Number Date Country
20100015602 A1 Jan 2010 US